Mazdutide

Last Updated: August 2026

Mazdutide (IBI362) is an investigational dual GLP-1/glucagon receptor agonist developed by Innovent Biologics and licensed from Eli Lilly's OXM-derived peptide platform. It is approved in China for obesity and type 2 diabetes, where the NMPA cleared it for chronic weight management in June 2025 and for glycaemic control in type 2 diabetes in September 2025; Innovent Biologics markets it as Xinermei®. It is not approved by the FDA or the EMA as of August 2026.

What is mazdutide and how does the GLP-1/glucagon dual mechanism work?

Mazdutide is an oxyntomodulin (OXM) analog activating both GLP-1 and glucagon receptors with a single molecule, producing GLP-1-mediated appetite suppression alongside glucagon-mediated direct energy expenditure and hepatic fat clearance. The glucagon component is the differentiating mechanism — same axis exploited by retatrutide (which adds GIP for triple agonism) and survodutide (the other Phase 3 dual GLP-1/glucagon). Evidence level: Approved in China on Phase 3 RCT data (weight management; type 2 diabetes); investigational / earlier-stage elsewhere.

What does the Phase 3 evidence show for mazdutide?

In the GLORY-1 Phase 3 trial conducted in China, mazdutide 6 mg produced an average weight loss of 14.4% over 48 weeks in Chinese adults with obesity versus 0.3% placebo, with continued weight reduction observed through extension. In type 2 diabetes (DREAMS-1), mazdutide reduced HbA1c by approximately 2.0 percentage points alongside weight reduction. The compound's efficacy in non-Asian populations has not yet been established at Phase 3 scale. Evidence level: Human RCT (Phase 3 in Chinese population).

How does mazdutide compare to survodutide and retatrutide?

Mazdutide and survodutide both engage the GLP-1/glucagon dual mechanism but are developed by different sponsors targeting different lead markets; retatrutide adds a third receptor (GIP) and produces larger weight loss at the cost of more complex synthesis. Mazdutide is uniquely China-led in clinical development.

What are the documented side effects of mazdutide?

The most common mazdutide side effects in GLORY-1 were gastrointestinal — nausea, diarrhea, and decreased appetite — generally mild and concentrated in dose escalation, with a profile similar to other GLP-1-class compounds. The glucagon component raised theoretical concerns about heart rate increases and hepatic effects, but Phase 3 data so far have not shown clinically significant cardiovascular signals. Long-term safety data is more limited than for semaglutide or tirzepatide. Evidence level: Human RCT (Phase 3).

What is the regulatory status of mazdutide?

Mazdutide is approved in China, where the NMPA cleared it for chronic weight management in June 2025 (adults with BMI ≥28, or ≥24 with a weight-related comorbidity) and for glycaemic control in type 2 diabetes in September 2025; Innovent Biologics markets it as Xinermei® (信尔美).1 source It is not approved by the FDA or the EMA as of August 2026, and no US Phase 3 program has been registered — a US filing would follow the China commercialization. Mazdutide is supplied as a research-use-only compound by third-party laboratories outside of the clinical trial population. Regulatory context in peptide legal status by country.

Why does mazdutide vendor verification matter for an early-stage compound?

Because mazdutide's manufacturing base is even narrower than other investigational GLP-1 compounds — production is concentrated in Chinese API laboratories with variable quality control — purity variance between vendors is wider than for semaglutide or tirzepatide. Independent HPLC purity testing and mass spectrometry identity confirmation are the only meaningful purity signals. Some research-grade vendors mislabel mazdutide as "GLP-1/Glucagon dual agonist" without specifying the molecule; buyers should confirm the specific compound. Interpretation guidance in our how-to-test-peptides hub.

How does Peptigrity verify mazdutide vendors?

Peptigrity collects independent third-party Certificates of Analysis for mazdutide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the cross-shop dataset for the compounds tested so far. Methodology in how we calculate trust scores.

Frequently Asked Questions

How can I verify a mazdutide vendor is selling real product?

The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay — and for mazdutide specifically, buyers should also verify the compound is labeled correctly, not as a generic "GLP-1/glucagon dual agonist." For COA interpretation, see red flags in peptide certificates of analysis.

Is mazdutide legal to purchase?

Mazdutide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Buyers are responsible for verifying local import rules — full breakdown in peptide legal status guide.

When will mazdutide be FDA-approved?

No US approval has been granted as of August 2026, and no US Phase 3 program has been registered. Mazdutide is already approved in China (June 2025 for weight management, September 2025 for type 2 diabetes, as Xinermei®); a US FDA filing, if pursued, would follow that commercialization and is not expected to yield approval before the late-2020s. Mazdutide may reach the Chinese market years before any Western jurisdiction. Track regulatory developments in FDA peptide regulation 2025–2026 timeline.

How does mazdutide compare to survodutide?

Both engage GLP-1 and glucagon receptors with similar mechanism logic but are developed by different sponsors — Innovent Biologics for mazdutide (China-led) versus Boehringer Ingelheim for survodutide (US/global). Head-to-head clinical data does not exist; comparing Phase 3 weight-loss numbers across non-matched populations is unreliable.

Does Peptigrity recommend a mazdutide dose?

No. Mazdutide is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. The doses studied in GLORY-1 and DREAMS-1 (3 mg, 4.5 mg, 6 mg weekly) were administered under clinical supervision. Anyone considering investigational compound use should consult a licensed physician.

Why is mazdutide cheaper than tirzepatide or semaglutide?

Because mazdutide is not FDA-approved, has no prescription product market, and is manufactured exclusively by research-grade Chinese laboratories without pharmaceutical-grade overhead. It also has substantially less safety data than the FDA-approved alternatives, which is part of why the price is lower. Current research-grade pricing context in how much do peptides cost.

This section is for educational and informational purposes only and does not constitute medical advice. Mazdutide is an investigational compound not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.